BioCentury | Oct 10, 2011
Clinical News

HVJ-E: Phase I/II start

...investigators will begin an open-label, Japanese Phase I/II trial evaluate intratumoral and subcutaneous injections of HVJ-E...
...Inc. (Tokyo:4563), Osaka, Japan TSD Japan Inc. , Osaka, Japan Product: HVJ-E ( GEN0101 , TSD-0014...
BioCentury | Jun 27, 2011
Company News

AnGes, TSD Japan deal partners to aid in the global development and commercialization of cancer candidate GEN0101 / TSD-0014...
BioCentury | Aug 14, 2008
Cover Story

Alnylam's RNAa Play

A study in Nature Structural & Molecular Biology proposes a mechanism for small RNA-induced gene activation, a process that results in upregulation of poorly expressed genes. 1 Although the jury is still out on what...
Items per page:
1 - 3 of 3